NVAX Novavax Dashboard

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Company profile

Ticker

NVAX

Exchange

NASDAQ

Website

www.novavax.com

CEO

Stanley Erck

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Exelixis ...

SEC CIK

0001000694

Corporate docs

Articles of Incorporation & Bylaws

IRS number

222816046

NVAX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

1 Aug 21

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

Understanding Novavax's Unusual Options Activity

26 Jul 21

Shares of Novavax (NASDAQ:NVAX) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $194.79.

Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next?

21 Jul 21

For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.

PreMarket Prep Stock Of The Day: Pfizer

20 Jul 21

Former NYSE Trader David Green: 'I Want To Buy AMC,' Thinks It's Going To Rise

20 Jul 21

Press releases

Pro users get this 30m faster

Thinking about trading options or stock in STMicroelectronics, Alibaba, Novavax, Pinduoduo, or Cassava Sciences?

29 Jul 21

NEW YORK, July 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STM, BABA, NVAX, PDD, and SAVA.

Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021

6 Jul 21

GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter

Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine

30 Jun 21

GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from

Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum

17 Jun 21

Thinking about trading options or stock in Sunrun, Trade Desk, Novavax, Ford, or Bank of America?

17 Jun 21

Calendar

10 May 21

1 Aug 21

31 Dec 21

Financial summary

Financial statements Chart NVAX financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Novavax earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.03B	2.03B	2.03B	2.03B	2.03B	2.03B
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	69.54M	50.2M	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	n/a	282.91M	204.24M	n/a	n/a
Cash remaining	n/a	n/a	1.75B	1.82B	n/a	n/a
Runway (months of cash)	n/a	n/a	25.1	36.3	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

NVAX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	204.5671	68	13.91K	706
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	203.4545	58	11.8K	774
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	202.5764	129	26.13K	832
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	201.5614	209	42.13K	961
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	200.4742	256	51.32K	1,170
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	199.466	224	44.68K	1,426
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	198.2032	317	62.83K	1,650
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	197.4697	485	95.77K	1,967
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	196.1202	313	61.39K	2,452
26 Jul 21	Herrmann John A III	Common Stock	Sell	Dispose S	No	Yes	195.2891	263	51.36K	2,765

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

NVAX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

56.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	383	347	+10.4%
Opened positions	100	98	+2.0%
Closed positions	64	53	+20.8%
Increased positions	98	114	-14.0%
Reduced positions	135	83	+62.7%

13F shares	Current	Prev Q	Change
Total value	7.6B	4.7B	+61.6%
Total shares	41.99M	38.88M	+8.0%
Total puts	3.55M	4.89M	-27.3%
Total calls	4.2M	3.35M	+25.3%
Total put/call ratio	0.8	1.5	-42.0%

Largest owners	Shares	Value	Change
Vanguard	5.89M	$1.07B	+5.3%
BLK Blackrock	5.47M	$992.32M	+6.8%
FMR	4.79M	$868.64M	+173.7%
Ra Capital Management	3M	$544.31M	-20.8%
STT State Street	1.44M	$261.44M	-16.5%
Wellington Management	1.42M	$258.08M	+289.2%
BEN Franklin Resources	1.31M	$236.68M	+2.1%
Geode Capital Management	1.11M	$200.89M	+15.6%
TROW T. Rowe Price	822.77K	$149.18M	+137.8%
NTRS Northern Trust	800.46K	$145.13M	-14.9%

Largest transactions	Shares	Bought/sold	Change
FMR	4.79M	+3.04M	+173.7%
Wellington Management	1.42M	+1.06M	+289.2%
Perceptive Advisors	0	-1.04M	EXIT
Ra Capital Management	3M	-786.48K	-20.8%
Susquehanna International	495.61K	-744.34K	-60.0%
Renaissance Technologies	672.68K	+672.68K	NEW
Capital World Investors	617.83K	-567.91K	-47.9%
Norges Bank	0	-558.69K	EXIT
Carmignac Gestion	529.17K	+529.17K	NEW
TROW T. Rowe Price	822.77K	+476.75K	+137.8%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Geovax Labs • Mymetics • Dynavax Technologies • Inovio Pharmaceuticals • ImmunityBio • Altimmune • Ocugen • Tonix Pharmaceuticals Holding • Selecta Biosciences • Can-Fite Biopharma

Risks

We are a biotechnology company and face significant risk in developing, manufacturing and commercializing our products.
Because we depend on third-parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.

Management Discussion

Revenue for the three months ended March 31, 2021 was $447.2 million as compared to $3.4 million for the same period in 2020, an increase of $443.9 million. Revenue for the three months ended March 31, 2021 was primarily comprised of revenue for services performed under the OWS Agreement and the CEPI Funding Agreement. Revenue for the three months ended March 31, 2020 was primarily comprised of revenue for services performed under the CEPI Funding Agreement, BMGF Grant Agreement and revenue from Novavax AB. The significant increase in revenue was due to increased development activities relating to NVX-CoV2373 under the OWS Agreement and the CEPI Funding Agreement.
We expect revenue in 2021 to significantly increase as compared with 2020 due to our NVX-CoV2373 program, which we anticipate will continue to be funded by OWS and CEPI and/or other revenue sources. Further, we anticipate bringing our NVXCoV2373 vaccine candidate to market following global regulatory approvals which, if achieved, should significantly increase revenue. In anticipation, we have entered into various advance purchase agreements as well as multiple supply and license agreements with strategic partners to supply NVX-CoV2373 in their specified territories under which we are entitled to receive royalty revenue from the sale of NVX-CoV2373 by such partners.
In the three months ended March 31, 2021, our research and development activities were primarily focused on the development of NVX-CoV2373 and included direct external research and development expenses related to NVX-CoV2373 of $538.1 million, primarily comprised of costs related to the following:

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: add, addressing, adolescent, African, allegedly, American, analytical, APA, APC, Asian, attended, back, Barnard, baseline, begun, boost, boosted, booster, boosting, breach, Burkina, Canadian, cardiovascular, Castle, catchment, CDMO, Centre, Chancery, characterization, CMC, CMO, complaint, composed, constituting, consulting, Council, Court, COVID, CRO, crossover, Delaware, demographic, description, disgorgement, durability, duty, East, en, endemic, enrichment, ensure, entry, escape, EUA, examination, examine, exhibit, exhibited, expansion, experienced, explore, exploring, Faso, fiduciary, forefront, foregoing, formally, formulated, Fourteen, frequency, fueled, fulfil, Golubinski, ground, GSK, hand, harmonized, headcount, Healthcare, HollisterStier, hypertension, IgG, Immunisation, IND, injection, internationally, inventory, Jenner, jointly, Jubilant, Kenya, Korean, la, Lancet, Latin, listing, lymph, Majesty, Mali, mechanism, Medsafe, Memorandum, memory, MHLW, MHRA, microgram, middle, Minister, mix, Montreal, MOU, Nanoro, Native, nominal, notably, obesity, online, open, optimistic, optimize, Oxford, parallel, pending, pipeline, plaintiff, PMDA, possessed, potent, predetermined, presence, prohibited, purport, purpose, quantity, Queen, randomly, raw, ready, reassuring, Recherche, regiment, rescinding, revoked, round, royalty, Sant, SAR, seronegative, seropositive, shortage, Spokane, stockholder, subset, summarized, Switzerland, Tanzania, TGA, thirty, tiered, today, unamortized, unbilled, Understanding, undisclosed, unique, unjust, unsatisfied, upfront, validation, variant, viability, Washington, waste, withholding, Zealand

Removed: academic, acceptable, acceptance, accessibility, accessible, account, accrued, adequately, adjustment, adjuvanted, adversely, affordable, Aid, allocating, allocation, aluminum, anniversary, assigning, asthma, awarded, biological, biopharmaceutical, BLA, blocked, bring, burden, calculate, calculated, Catalent, certainty, charge, China, choice, chronic, closed, collectively, combat, commercialized, competitive, competitor, conditional, confidence, congestive, contemplated, continuity, convenient, core, CoV, create, curtailed, customer, cybersecurity, decade, declared, decreased, deduction, deemed, degree, delayed, derived, developed, difficult, diminished, diminishing, disaster, disclosed, disrupted, disruption, distancing, dosing, dramatic, Ebola, EBOV, economic, eliminating, emerged, enacted, enactment, enhanced, escrow, essentially, establish, exacerbation, execute, expensive, experience, extensive, extreme, failed, failure, family, fatal, fewer, flu, forecast, fringe, GACA, genetic, geographic, GlaxoSmithKline, glycoprotein, governmental, GP, grow, healthy, heart, heavily, home, hospital, identify, immunosenescence, impairment, imposed, impossible, inadequate, inception, incidence, independently, indirect, indirectly, industry, Inovio, insect, institution, invest, investor, Johnson, July, Larger, licensing, longer, lot, LRTI, manner, marketing, Maryland, maternal, measurement, meet, minimum, Moderna, mortality, natural, necessitate, negatively, obstructive, occur, offering, outbreak, overhead, Paragon, paused, people, perform, personnel, Pfizer, phosphate, political, power, predicted, pregnant, preliminary, Prepare, prioritization, produced, professional, prolongation, prospectively, prove, proven, pulmonary, pursue, pursuing, quality, quantitative, rapid, reaching, record, recruitment, reduced, reducing, regulated, reimbursed, relief, remotely, requirement, resulted, ResVax, ResVaxTM, safer, Sanofi, satisfy, School, season, sequence, side, social, spread, step, substantial, subtracting, successful, successfully, surface, target, terrorism, test, threat, timely, tract, travel, treated, trimester, twelve, type, uncertain, uncertainty, Union, unpredictable, utilized, viral, volatile, vulnerable, waiting, war, water, weather, women

From filing 10-Q 2021 Q1